Novo Nordisk Downgraded to Hold by HSBC Amid Concerns Over Growth Trajectory
ByAinvest
Saturday, Aug 2, 2025 5:10 am ET1min read
NVO--
The downgrade is attributed to several factors, including the continued illegal selling of weight loss drugs by U.S. compounders despite FDA bans, which has prevented Novo Nordisk from regaining expected market share in the GLP-1 drug market [2]. Additionally, HSBC raised concerns about the overestimation of the GLP-1 market size and questioned the safety of medium-term pricing assumptions given capacity investments in the space [2].
HSBC acknowledged that their previous Buy rating was incorrect, noting that their assumption about the FDA ban on compounding allowing Novo Nordisk to regain market share has not materialized [2]. The research firm also highlighted internal management changes and execution delays as factors contributing to the reduced confidence in Novo Nordisk's short-term earnings outlook [2].
The downgrade reflects a broader trend of concern over Novo Nordisk's growth trajectory and structural weaknesses in the GLP-1 market, which underpins much of the company's sales momentum [2]. Earnings for 2025 and 2026 have been revised downward by 5% and 16%, respectively, with HSBC lowering its target price from DKK680 to DKK360 [2].
References:
[1] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916407
[2] https://seekingalpha.com/news/4475685-novo-nordisk-downgraded-to-hold-at-hsbc-on-guidance-cut
Novo Nordisk was downgraded to Hold from Buy at HSBC due to the company's warning that its 2025 exit growth rate will likely settle into mid-single digits. The adjustment reflects concerns over Novo Nordisk's growth trajectory and structural challenges.
Novo Nordisk, a leading global healthcare company, has been downgraded to Hold from Buy by HSBC, reflecting mounting concerns over the company's growth trajectory and structural challenges. The downgrade comes following Novo Nordisk's recent warning that its 2025 exit growth rate is expected to settle into mid-single digits [1].The downgrade is attributed to several factors, including the continued illegal selling of weight loss drugs by U.S. compounders despite FDA bans, which has prevented Novo Nordisk from regaining expected market share in the GLP-1 drug market [2]. Additionally, HSBC raised concerns about the overestimation of the GLP-1 market size and questioned the safety of medium-term pricing assumptions given capacity investments in the space [2].
HSBC acknowledged that their previous Buy rating was incorrect, noting that their assumption about the FDA ban on compounding allowing Novo Nordisk to regain market share has not materialized [2]. The research firm also highlighted internal management changes and execution delays as factors contributing to the reduced confidence in Novo Nordisk's short-term earnings outlook [2].
The downgrade reflects a broader trend of concern over Novo Nordisk's growth trajectory and structural weaknesses in the GLP-1 market, which underpins much of the company's sales momentum [2]. Earnings for 2025 and 2026 have been revised downward by 5% and 16%, respectively, with HSBC lowering its target price from DKK680 to DKK360 [2].
References:
[1] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916407
[2] https://seekingalpha.com/news/4475685-novo-nordisk-downgraded-to-hold-at-hsbc-on-guidance-cut

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet